[ad_1]
German biotechnology company BioNTech announced that the construction of the facility where plasmid DNA, an important component of mRNA-based vaccines, will be produced at its factory in Marburg, has been completed.
In the statement made by BioNTech, it was stated that 40 million euros will be invested in the completed facility.
In the statement, it was stated that most of the plasmid DNA components needed for mRNA-based drugs for cancer and infectious diseases will be produced in this facility.
“EPIDDEN PROVIDED GERMANY’S INNOVATION CAPABILITY”
Visiting the facility in Marburg, about 90 kilometers north of Frankfurt Germany Prime Minister Olaf Scholz stated that they welcome the investment of BioNTech.
Scholz said, “Medical biotechnology is the key technology of the 21st century. The Covid-19 pandemic has proven Germany’s ability to be a place of innovation and drug production. Germany and Europe are becoming more flexible by creating local value chains. This investment by BioNTech is very good news. You can see and feel that this is truly the future.” he said.
Stressing that more needs to be done to help Germany’s biotech companies open such factories faster, develop new treatments and bring their products to market, Scholz said, including better access to data for research purposes. health promised to work to improve the legal framework for its companies.
BioNTech, co-founder of Turkish scientist Uğur Şahin, purchased the Marburg facility from the pharmaceutical company Novartis, headquartered in Switzerland, in 2020.
[ad_2]
